Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.

Hussain, Maha; Carducci, Michael A; Slovin, Susan; Cetnar, Jeremy; Qian, Jiang; McKeegan, Evelyn M; Refici-Buhr, Marion; Chyla, Brenda; Shepherd, Stacie P; Giranda, Vincent L; Alumkal, Joshi J

Hussain, Maha; Carducci, Michael A; Slovin, Susan; Cetnar, Jeremy; Qian, Jiang; McKeegan, Evelyn M; Refici-Buhr, Marion; Chyla, Brenda; Shepherd, Stacie P; Giranda, Vincent L; Alumkal, Joshi J.

Affiliation

Hussain M; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA, mahahuss@med.umich.edu.

Invest New Drugs ; 32(5): 904-12, 2014 Oct.

Article in En | MEDLINE | ID: mdl-24764124

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Prostatic Neoplasms, Castration-Resistant/drug therapy; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/pharmacology; Benzimidazoles/administration & dosage; Benzimidazoles/adverse effects; DNA Repair/drug effects; Dacarbazine/administration & dosage; Dacarbazine/adverse effects; Dacarbazine/analogs & derivatives; Humans; Kallikreins/blood; Male; Middle Aged; Pilot Projects; Poly(ADP-ribose) Polymerase Inhibitors; Prostate-Specific Antigen/blood; Prostatic Neoplasms, Castration-Resistant/blood; Temozolomide; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Prostatic Neoplasms, Castration-Resistant Type of study: Clinical_trials Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Invest New Drugs Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google